文献速递其他结缔组织病

幼年皮肌炎长期随访中持续活动性疾病预测因素及器官损害、患者报告结局和自身抗体的纵向发展

Predictors of persistent active disease and the longitudinal development of organ damage, patient-reported outcomes and autoantibodies in long-term juvenile dermatomyositis.
PubMed 文献 · RMD Open · 2025-06-05

该研究对40例幼年皮肌炎(JDM)患者在两个时间点进行临床评估,中位病程从症状出现至第2次访视为21.7年。第2次访视时53%患者仍存在活动性疾病(PRINTO标准),95%存在器官损害(MDI总分≥1),40%存在身体功能受损。首次访视时较高的疾病活动度和器官损害可预测随访时持续活动性疾病。

要点

  • 第2次访视时53%患者仍存在活动性疾病(PRINTO标准)。
  • 第2次访视时95%患者存在器官损害(MDI总分≥1)。
  • 首次访视时较高的疾病活动度和器官损害预测持续活动性疾病。

核心结论

  • JDM患者在中位病程21.7年后,多数仍存在活动性疾病。
  • 首次访视时较高的器官损害和疾病活动度可预测随访时持续活动性疾病。
  • 结果强调JDM的慢性性质,需要加强早期和长期管理策略以改善患者结局。

研究设计与样本

  • 对40例(65%女性)诊断为JDM的患者在两个不同时间点(访视1和访视2)进行临床检查。
  • 采用更新的PRINTO标准和幼年皮肌炎活动指数(JDMAI)评估临床非活动/活动性疾病。
  • 采用肌炎损害指数(MDI)评估器官损害,采用儿童健康评估问卷(CHAQ/HAQ)评估身体功能。
  • 采用肌炎线性免疫分析法检测肌炎自身抗体。

主要发现

  • 从症状出现起中位病程在访视1为15.1(2.0-34.6)年,在访视2为21.7(7.6-42.7)年。
  • 访视2时,活动性疾病(PRINTO)见于53%患者,身体功能受损(CHAQ/HAQ>0)见于40%患者,器官损害(MDI总分≥1)见于95%患者,肌炎特异性或相关性抗体见于33%患者。
  • 访视2时疾病活动度(JDMAI)低度见于24%患者,中度见于8%患者,高度见于3%患者。
  • 两次访视间器官损害和疾病活动度无显著差异。
  • 访视1时较高的疾病活动度和器官损害可预测访视2时持续活动性疾病。

关键数值与推荐

  • 活动性疾病(PRINTO标准)在访视2见于53%患者。
  • 器官损害(MDI总分≥1)在访视2见于95%患者。
  • 身体功能受损(CHAQ/HAQ>0)在访视2见于40%患者。
  • 肌炎特异性或相关性抗体在访视2见于33%患者。
  • 疾病活动度(JDMAI)在访视2低度见于24%、中度见于8%、高度见于3%患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify longitudinal development of disease activity, organ damage, patient-reported outcomes, and myositis autoantibody profiles in patients with juvenile dermatomyositis (JDM) after long-term follow-up, and to identify predictors for persistent active disease. METHODS: Forty patients (65% female) diagnosed with JDM were clinically examined at two different time points (visits 1 and 2). We assessed clinically inactive/active disease by the updated PRINTO criteria and the Juvenile DermatoMyositis Activity Index (JDMAI). Organ damage was evaluated by Myositis Damage Index (MDI) and physical function by Childhood Health Assessment Questionnaire (CHAQ/HAQ). Myositis autoantibodies were measured by myositis line immunoassay. RESULTS: Median disease duration from symptom onset was 15.1 (2.0-34.6) at visit 1 and 21.7 (7.6-42.7) years at visit 2. At visit 2, active disease (PRINTO) was found in 53%, impaired physical function (CHAQ/HAQ>0) in 40%, organ damage (MDItotal≥1) in 95% and myositis specific or associated antibodies in 33% of patients. Disease activity (JDMAI) was low in 24%, moderate in 8% and high in 3% of patients. There were no significant differences in organ damage and disease activity between visits. Higher disease activity and organ damage at visit 1 predicted persistent active disease at visit 2. CONCLUSIONS: After a median of 21.7 years from symptom onset, the majority of JDM patients still had active disease. Higher organ damage and disease activity at the initial visit predicted persistent active disease at follow-up. These results underscore the chronic nature of JDM, emphasising the need for enhanced early and long-term management strategies to improve patient outcomes.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Berger SG, Berntsen KS, Risum K, et al. Predictors of persistent active disease and the longitudinal development of organ damage, patient-reported outcomes and autoantibodies in long-term juvenile dermatomyositis. RMD Open. 2025. PMID: 40480648. doi:10.1136/rmdopen-2025-005598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。